Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Lenvatinib Mesylate
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: Lenvatinib Mesylate
Price: ￥486.0/50mg ￥1566.0/1g ￥4666.0/5g ￥826.0/250mg
Purity: 97.0%
Stocking Period: 1 Day
Contact: Liu jia
Email: 2130147988@qq.com

DC Chemicals Limited
China
Product Name: LENVATINIB MESYLATE
Price: $200.0/100mg $400.0/250mg $800.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

ShangHai DC Chemicals Co.,Ltd
China
Product Name: LENVATINIB MESYLATE
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Lai
Email: order@dcchemicals.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: lenvatinib Mesylate
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

857890-39-2

857890-39-2 structure

857890-39-2 structure

Name: Lenvatinib Mesylate
Chemical Name: lenvatinib mesylate
CAS Number: 857890-39-2
Molecular Formula: C₂₂H₂₃ClN₄O₇S
Molecular Weight: 522.959
Catalog: Biochemical Inhibitor Protein tyrosine kinase
Create Date: 2018-07-20 22:37:53
Modify Date: 2025-08-25 18:05:11
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

Name	lenvatinib mesylate
Synonyms	4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide mesylate Lenvatinib mesilate lenvatinib mesylate Lenvatinib mesylate [USAN] 4-{3-Chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxy-6-quinolinecarboxamide methanesulfonate (1:1) 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide,methanesulfonic acid 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) Lenvatinib mesilate (JAN) lenvatinib methanesulfonate UNII-3J78384F61

Description	Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit
Target	VEGFR1:22 nM (IC50) VEGFR2:4 nM (IC50) VEGFR3:5.2 nM (IC50) FGFR1:46 nM (IC50) FGFR2 FGFR3 FGFR4 PDGFRα:51 nM (IC50) PDGFRβ:39 nM (IC50) c-Kit:100 nM (IC50) RET
In Vitro	Lenvatinib mesylate (E7080 mesylate) has IC50s of 4, 5.2, 22 nM for VEGFR2(KDR), VEGFR3(Flt-4), and VEGFR1/Flt-1, respectively. Lenvatinib inhibits PDGFRα, PDGFRβ, FGFR1, and KIT with IC50s of 51, 39, 46, 100 nM, respectively[3].
In Vivo	Lenvatinib mesylate (E7080 mesylate) (100 mg/kg, p.o.) is administeredand bevacizumab significantly inhibits local tumor growth at the m.f.p., and at the end of treatment, Lenvatinib mesylate also significantly inhibits metastasis to both regional lymph nodes and distant lung[3]. Lenvatinib mesylate (E7080 mesylate) inhibits the growth of H146 tumor at 30 and 100 mg/kg (BID, QDx21) in a dose-dependent manner and causes tumor regression at 100 mg/kg in H146 xenograft model. IHC analysis with anti-CD31 antibody shows that lenvatinib at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and imatinib treatment[4].
References	[1]. Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. [2]. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. [3]. 3.Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545. [4]. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671.

Molecular Formula	C₂₂H₂₃ClN₄O₇S
Molecular Weight	522.959
Exact Mass	522.097595
PSA	182.80000
LogP	5.81830

417716-92-8 structure

417716-92-8

75-75-2 structure

75-75-2

~%

857890-39-2 structure

857890-39-2

Literature: Eisai Co., Ltd. Patent: EP1698623 A1, 2006 ; Location in patent: Page/Page column 17 ;

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.